206 related articles for article (PubMed ID: 36272969)
21. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
Gittelman M; Jaffe JS; Kaminetsky JC
J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
[TBL] [Abstract][Full Text] [Related]
22. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
Permpongkosol S; Tantirangsee N; Ratana-olarn K
J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
[TBL] [Abstract][Full Text] [Related]
23. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism.
Pencina KM; Travison TG; Cunningham GR; Lincoff AM; Nissen SE; Khera M; Miller MG; Flevaris P; Li X; Wannemuehler K; Bhasin S
J Clin Endocrinol Metab; 2024 Jan; 109(2):569-580. PubMed ID: 37589949
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
McMahon CG; Shusterman N; Cohen B
J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
[TBL] [Abstract][Full Text] [Related]
25. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
26. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
27. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men.
White WB; Dobs A; Carson C; DelConte A; Khera M; Miner M; Shahid M; Kim K; Chidambaram N
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):630-637. PubMed ID: 34191621
[TBL] [Abstract][Full Text] [Related]
28. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men.
Yin A; Alfadhli E; Htun M; Dudley R; Faulkner S; Hull L; Leung A; Bross R; Longstreth J; Swerdloff R; Wang C
J Androl; 2012; 33(6):1282-90. PubMed ID: 22790645
[TBL] [Abstract][Full Text] [Related]
29. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
[TBL] [Abstract][Full Text] [Related]
30. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
[TBL] [Abstract][Full Text] [Related]
31. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism.
DelConte A; Papangkorn K; Kim K; Bruno BJ; Chidambaram N; Khera M; Goldstein I; Kohler TS; Miner M; Dobs AS; Patel MV
Andrology; 2022 May; 10(4):669-676. PubMed ID: 34994093
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
33. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
34. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
35. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
Zitzmann M; Nieschlag E
J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
[TBL] [Abstract][Full Text] [Related]
37. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
38. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
[TBL] [Abstract][Full Text] [Related]
39. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
40. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
